Theodore Schroeder is the President, CEO, Director and co-founder of Zavante Therapeutics, Inc. Previously, Mr. Schroeder co-founded Cadence Pharmaceuticals, Inc. (acquired by Mallinckrodt) and served as its President and Chief Executive Officer, and as a member of the Board of Directors. Prior to co-founding Cadence he held several roles at Elan Pharmaceuticals, including Senior Vice President of North America Sales and Marketing and Vice President and General Manager of the Hospital Products Business Unit, a role he also held at Dura Pharmaceuticals (acquired by Elan). Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb. Mr. Schroeder currently serves on the Boards of Directors of Cidara Therapeutics and Otonomy, Inc. Mr. Schroeder is a member of the Sharp Hospital Foundation board and chair of the BIOCOM board of directors. He holds a bachelor’s degree in management from Rutgers University.